|Slideshows|November 16, 2020

Statistics of Suicide

Here are some statistics around suicide to help put things in perspective.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Models for Self-Harm and Suicide Risk, Review With Investigator Seena Fazel, MD

BySeena Fazel, MBChB, MD, FRCPsych

November 19th 2025

Making Chatbots Safe For Suicidal Patients

ByAllen Frances, MD,Ursula Whiteside, MD

November 18th 2025

Meeting the Needs of Veteran Patients

ByEugene T. Lucas Jr, DNP, CRNP, FNP-BC, APMHNP-BC

November 11th 2025

Correctional Psychiatry Enters a New Era: NCCHC Releases 2026 Mental Health Standards

ByKim Sterling

November 3rd 2025

Opening the Conversation About Suicidality

BySusan J. Noonan, MD, MPH

October 31st 2025

Latest CME

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Statistics of Suicide

Newsletter

Related Content

Models for Self-Harm and Suicide Risk, Review With Investigator Seena Fazel, MD

Making Chatbots Safe For Suicidal Patients

Meeting the Needs of Veteran Patients

Correctional Psychiatry Enters a New Era: NCCHC Releases 2026 Mental Health Standards

Opening the Conversation About Suicidality

Latest CME

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

FDA Clears Investigational New Drug Application for TNX-102 SL for Treatment of Major Depressive Disorder

Lecanemab or Lithium? Compare Benefits, Risks, and Dose

Use of TMS in Treatment of Depression, Discussion With Rachel Rohaidy, MD

The Epstein Files, the Abuse of Women, and Psychiatry

Vagus Nerve Stimulation in Treatment Resistant Depression: New Lines of Thinking